485 Results (Page 16 of 20)
China Markets Research Reports
China Clinical Trials Support Service Market Analysis
This report presents a strategic analysis of the China Clinical Trials Support Service Market and a forecast for its development in the medium and long term. It provides a broad overview of the market dynamics, trends and insights, growth drivers and restraints, segmentation, competitive landscape, healthcare policies and regulatory framework, reimbursement scenario, challenges and future outlook. This is one of the most comprehensive reports about the China Clinical Trials Support Service Market, offering unmatched value, accuracy and expert insights.
China Diabetes Therapeutics Market Analysis
China's diabetes therapeutics market is expected to grow from $11.56 Bn in 2022 to $27.04 Bn in 2030 with a CAGR of 11.2% for the forecasted year 2022-2030. The rise in the ageing population of China and the introduction of novel therapeutic options in China are the major growth drivers of the market. The China diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Yunnan Baiyao, Kangmei Pharmaceutical, and Eli Lilly are the major players in the China diabetes therapeutics market.
China Cancer Immunotherapy Market Analysis
China's cancer immunotherapy market is expected to grow from $9.04 Bn in 2022 to $17.50 Bn in 2030 with a CAGR of 8.6% for the forecasted year 2022-2030. A larger patient pool suffering from cancer in China and the increased funding from the Chinese government for R&D in cancer immunotherapy are driving the growth of the market. The China cancer immunotherapy market is segmented by type, application, and end user. BeiGene, Legend Biotech, and AstraZeneca are the major players in the China cancer immunotherapy market.
China Digital Health Market Analysis
China's Digital Health market is projected to grow from $16.96 Bn in 2022 to $73.42 Bn by 2030, registering a CAGR of 20.1% during the forecast period of 2022-30. Driven by national initiatives, population expansion, and diversified healthcare requirements, China's healthcare industry is experiencing faster innovation and adoption. The market is segmented by solution, by deployment, and by end-use. Some of the major players include Alibaba Group Holding Limited, Ping An Good Doctor & Cerner Corporation.
China Chronic Obstructive Pulmonary Disease (COPD) Therapeutics Market Analysis
China's Chronic Obstructive Pulmonary Disease (COPD) therapeutics market was valued at $1.46 Bn in 2022 and is estimated to expand at a CAGR of 8.6% from 2022 to 2030 and will reach $2.84 Bn in 2030. One of the main reasons propelling the growth of this market is the increased prevalence rate, air pollution, and smoking. The market is segmented by drug class and by distribution channel. Some key players in this market are Sinopharm Group, Hutchison China MediTech, Zhejiang Hisun Pharmaceutical, Haisco Pharmaceutical Group, Shanghai Sine Promod Pharmaceutical, Astellas Pharma, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Novartis, Pfizer, Teva China Limited and others.
China Dermatology Drugs Market Analysis
By 2030, it is anticipated that the China Dermatology drugs market will reach a value of $3.46 Bn from $1.37 Bn in 2022, growing at a CAGR of 12.3% during 2022-2030. The dermatology drug market in China is dominated by a few large pharmaceutical companies such as Johnson and Johnson Shanghai, China Resources Pharmaceutical Group and Chongqing Huapont Pharm. The dermatology drug market in China is segmented by drug class, drug type, prescription mode, indication, route of administration, end-user, and distribution channel. The major factors affecting the China dermatology drugs market are the increasing disease burden of non-communicable diseases like cancer and the lack of healthcare facilities for cancer treatment in most areas of China.
China Telemedicine Market Analysis
China's telemedicine market size is at around $4.88 Bn in 2022 and is projected to reach $20.6 Bn in 2030, exhibiting a CAGR of 19.7% during the forecast period 2022-2030. China's Telemedicine Market is segmented by component, modality, delivery mode, and facility. Changes in healthcare insurance coverage and restrictions have a substantial impact on people's out-of-pocket expenses, which fuels the Chinese telemedicine market's demand. Some of the top players are Ping An Healthcare & Technology Co., Alibaba Health Information Technology Ltd., JD Health International Inc., and Medix.
China ECG Equipments Market Analysis
The China ECG Equipment Market is expected to witness growth from $716 Mn in 2022 to $1406 Mn in 2030 with a CAGR of 8.80% for the forecasted year 2022-2030. In China, heart illness is one of the main causes of death and is becoming more common. Due to this, the need for ECG equipment to diagnose and track heart disease is on the rise. The market is segmented by product type and by the end user. Some key players in this market include Mindray, Edan Instruments, Johnson & Johnson, Philipps Healthcare, Medtronic, Biolight and Dexcom.
China Connected Healthcare Market Analysis
The China-connected healthcare market is projected to grow from $5.34 Bn in 2022 to $43.25 Bn by 2030, registering a CAGR of 29.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be a large and ageing population, government support, technological advancements and a rising middle class. The market is segmented by type, function and by application. Some of the major players include Tencent Health, JD Health International, WeDoctor, iCarbonX, Roche, GE Healthcare and Medtronic.
China Oncology Therapeutics Market Analysis
By 2030, it is anticipated that the China Oncology Therapeutics Market will reach a value of $31.1 Bn from $14.6 Bn in 2022, growing at a CAGR of 9.9% during 2022-2030. The Oncology Therapeutics Market in China is dominated by a few domestic pharmaceutical companies such as Bristol Myers Squibb, Boehringer Ingelheim, and CureVac. The Oncology Therapeutics Market in China is segmented into different types of cancer and different therapy type. The major risk factors associated with cancer are diet, alcohol, tobacco, air pollution, and physical inactivity. The demand for China Oncology Therapeutics is increasing on account of the rise in initiatives taken by the Government of the country.
China Biomaterials in Healthcare Market Analysis
The China Biomaterials Healthcare Market is expected to witness growth from $12.56 Bn in 2022 to $37.62 Bn in 2030 with a CAGR of 14.70% for the forecasted year 2022-2030. One of the world's biggest ageing populations is found in China. Medical implants and devices made of biomaterials are in greater demand as the population ages in China. The market is segmented by type and by application. Some key players in this market include Weigao Group, Suzhou Sinomed, MicroPort, BASF SE, Celanese, Covestro AG and Evonik Industries.
China Liver Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the China liver cancer therapeutics market will reach a value of $953.6 Mn from $235.5 Mn in 2022, growing at a CAGR of 19.1% during 2022-30. The liver cancer therapeutics market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Chi-Med, and Jiangsu HengRui Medicine. The liver cancer therapeutics market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting this market are the growing prevalence of liver cancer and the high cost and side effects related to certain liver cancer therapies.
China Lung Cancer Therapeutics Market Analysis
By 2030, it is anticipated that the China Lung Cancer Therapeutics Market will reach a value of $5 Bn from $2.4 Bn in 2022, growing at a CAGR of 9.6% during 2022-2030. The Lung Cancer Therapeutics Market in China is dominated by a few domestic pharmaceutical companies such as BeiGene, Jiangsu Hengrui Medicine, and Hutchison. The Lung Cancer Therapeutics Market in China is segmented into different types of cancer and different therapy type. Some of the major factors affecting the China lung cancer therapeutics market are the prevalence of unhealthy lifestyles, demand for targeted therapies and the presence of highly efficient drugs.
China Diabetes Devices Market Analysis
The China Diabetes Devices Market is expected to grow from $1.82 Bn in 2022 to $3.56 Bn in 2030 with a CAGR of 8.70% for the forecasted year 2022-2030. Diabetes is a common condition in China, where the demand for diabetes-related products and devices is rising. The prevalence of diabetes is anticipated to increase as the population ages and urbanizes, providing significant opportunities for diabetes device manufacturers. The market is segmented by type and by the end user. Some key players in this market include Lepu Medical Technology, MicroPort, Johnson & Johnson, Medtronic, Roche, Ascensia Diabetes Care and Dexcom.
China Cardiac Surgery Instruments Market Analysis
The China Cardiac Surgery Instruments Market is expected to witness growth from $166 Mn in 2022 to $310 Mn in 2030 with a CAGR of 8.10% for the forecasted year 2022-2030. In China, due to rising disposable income, more people in China can now access better healthcare services like cardiac surgeries. This has increased demand for cardiac surgery equipment, providing manufacturers with new business opportunities. The market is segmented by type, application and by end user. Some key players in this market include Lepu Medical Technology, MicroPort, LivaNova, B. Braun, Medline Industries, KLS Martin, and STILLE.
China Cardiovascular Diseases Therapeutics Market Analysis
China's cardiovascular disease therapeutics market is expected to witness growth from $13.07 Bn in 2022 to $25.52 Bn in 2030 with a CAGR of 8.72% for the year 2022-30. The shifting lifestyle modifications in China have led to an increase in the prevalence of cardiovascular diseases, therefore, driving the growth of the market. The China cardiovascular disease therapeutics market is segmented by disease indication, drug type, route of administration, drug classification, mode of purchase, and by the end user. Lanrui Boyan Medical, Beijing Handian Pharmacy, and AstraZeneca are the major players in the China cardiovascular disease therapeutics market.
China Healthcare Insurance Market Analysis
The China healthcare insurance market is projected to grow from $162.88 Bn in 2022 to $326.94 Bn by 2030, registering a CAGR of 9.1% during the forecast period of 2022 - 2030. The main factors driving the growth would be increasing health insurance premiums, growing awareness of health risks and rising medical costs. The market is segmented by component, the provider, coverage, health insurance plans and end-user. Some major players include Ping and Insurance, China Life Insurance, People’s Insurance, China Pacific Insurance and New China Life Insurance.
China Healthcare Claims Management Market Analysis
The China healthcare claims management market is projected to grow from $2.15 Bn in 2022 to $12.71 Bn by 2030, registering a CAGR of 24.9% during the forecast period of 2022 - 2030. The main factors driving the growth would be the growing adoption of digital healthcare, increasing healthcare fraud, government initiatives and increasing healthcare spending. The market is segmented by component, type, delivery mode and by end-user. Some of the major players include Ping a Healthcare, China Pacific Insurance, Cognizant, Allianz and Cigna.
China Diagnostic Imaging Services Market
The China Diagnostic Imaging Services market size was valued at $42 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 4.9 % from 2022 to 2030 and will reach $61.58 Bn in 2030. The market is segmented by product, application, and end user. The China Diagnostic Imaging Services market will grow as the development of new 3D printing materials and techniques has led to the production of more complex and customizable medical devices. The key market players are Canon Medical Systems Corporation, Carestream Health Inc., Esaote SpA, FUJIFILM Holdings Corporation, and GE Healthcare.
China Oncology Clinical Trials Market Analysis
China's oncology clinical trials market is projected to grow from $1.02 Bn in 2022 to $1.75 Bn by 2030, registering a CAGR of 7% during the forecast period of 2022-30. The market will be driven by the rising incidence of cancer in the country and efforts to promote research, collaboration, and innovation. The market is segmented by phase, by study design & by indication. Some of the major players include Novartis AG, Roche Holding AG, Jiangsu Hengrui Pharmaceutical & Sino Biopharmaceutical.
China Diabetes Drugs Market Analysis
The China diabetes drugs market size was valued at $4.96 Bn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 7.6% from 2022 to 2030 and will reach $8.9 Bn in 2030. The market is segmented by drug type, application, and distribution channel. The China diabetes drug market will grow because China is the country with the largest population of people with diabetes in the world. The key market players are Gan & Lee Pharmaceuticals (CHN), Tonghua Dongbao Pharmaceutical (CHN), Jiangsu Hengrui Medicine (CHN), and others.
China Alexipharmic Drugs Market Analysis
China's Alexipharmic drugs market size was valued at $xx Bn in 2022 and is estimated to expand at a CAGR of 6.20% from 2022-30 and will reach $xx Bn in 2030. The market is segmented by product type, indication, route of administration, end-user, and distribution channel. The China Alexipharmic Drugs market will grow because the Chinese government and healthcare providers are increasing their efforts to raise public awareness about poisoning and the availability of antidotes. The key market players are Beijing Kawin Technology Share-Holding (CHN), Yino Pharma Limited (CHN), and others.
China Neurology Clinical Trials Market Analysis
The China Neurology Clinical Trials market is projected to grow from $420.4 Mn in 2022 to $722.4 Mn by 2030, registering a CAGR of 7% during the forecast period of 2022 - 2030. The market will be driven by the country's increasing incidence of neurological disorders and pharmaceutical firms boosting their investments in R&D. The market is segmented by phase, by study design & by indication. Some of the major players include Pfizer, Novartis, Shanghai Green Valley Pharmaceuticals & Jiangsu Hengrui Medicine.
China Teleradiology Market Analysis
The China Teleradiology market size was valued at $191 Mn in 2022 and is estimated to expand at a compound annual growth rate (CAGR) of 12.20% from 2022 to 2030 and will reach $ 514 Mn in 2030. The market is segmented by application, modality, technology solutions, and end user. The China teleradiology market will grow due to Increasing demand for remote radiology services. The key market players are United Imaging Healthcare (UIH), AliHealth, Nanjing Remote Medical Imaging (NRMI), Beijing Deepwise & League of PHD Technology (DL), Yitu Healthcare, and others.
China Alzheimer’s Disease Drugs Market Analysis
The China Alzheimer’s Disease Drugs market was valued at $1.24 Bn in 2022 and is estimated to expand at a CAGR of 9.42% from 2022-30 and will reach $2.64 Bn in 2030. One of the main reasons propelling the growth of this market is government support, and the aging population. The market is segmented by drug classes and by Distribution Channels. Some key players in this market are Shanghai Green Valley Pharmaceutica, Eisai Co., Eli Lilly and Company, H. Lundbeck A/S, Johnson and Johnson, Hengrui Medicine Co, Jiangsu Hengrui, Novartis AG, Chongqing Zhifei Biological Products, Pfizer and CSPC Pharmaceutical Group among others.